Supplementary Figure 2
Supplementary Figure 2. Glycosylation profile as assessed by flow cytometry of (a) murine and (b) human platelets following incubation with anti-GPIbα mAbs. Exposed galactose was detected with Ricinus Communuis Agglutinin (RCA-1), Gal-β(1,3)GalNAc was detected with Peanut Agglutinin (PNA), sialic acids in α2,6 and α2,3 linkages were detected with Sambucus Nigra Lectin (SNA) and Maackia Amurensis Lectin II (MAL II) respectively. Although only significantly increased binding of PNA was observed on murine platelets, increased binding of all the lectins to human platelets occurred following anti-GPIbα mAbs incubations. We postulate additional sialic acids may originate from released platelet contents, such as VWF or P-selectin, following antibody mediated activation, netting in an overall lack of significant change or increase in surface sialic content. n=6. Anti-GPIbα mAbs shown as mean ± SEM of individual mAbs. *P<0.05, **P<0.01, ***P<0.001 vs. CTRL as determined by Student's t-test. Figure 4 . Anti-GPIIbIIIa antibodies does not cause platelet NEU1 surface expression (a) Confocal images of human platelets and isotype control (non-specific rabbit polyclonal IgG). (b,c) Representative confocal images of surface expression of NEU1 on murine (a) and human (c) platelets stained with anti-NEU1 and anti-CD41 following incubations with anti-GPIIbIIIa mAb (9D2 (murine), PSI C1 (human)) or anti-GPIIbIIa sera (murine). NEU1 positivity similar to control sera treated platelets (Fig. 2a) , and does not appear to co-localize with platelet surface marker CD41. All other mAbs were also tested with similar results. n=5-8. Red scale bars are 1μM, yellow scale bars are 5μM. Supplementary Figure 7: (a) Anti-GPIbα mAb induces thrombocytopenia in FcγR -/-mice. Indicated mAbs were injected into WT Balb/C or FcγR -/-at the same dose (b) Anti-GPIbα but not anti-GPIIbIIIa mAb mediated thrombocytopenia is less severe in Aspgr2 -/-mice compared with WT control. Indicated mAbs were injected into WT C75/BL6 or Aspgr2 -/-at the same dose. Platelet enumeration was done immediately prior to mAb injection (time 0) and 24 hours following (time 24). *P<0.05, **P<0.01, ***P<0.001 as determined by Student's t-test.
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